What diseases are included in the indications of neratinib/neratinib?

Neratinib/Neratinib (Neratinib) is an oral, irreversible pan-HER receptor tyrosine kinase inhibitor that mainly acts on HER1, HER2 and HER4 receptors and has broad-spectrum anti-tumor activity. The drug is mainly approved for the treatment of patients with HER2-positive breast cancer, especially in the consolidation treatment after traditional HER2-targeted therapy, showing unique value. Its indications cover the treatment targets of multiple stages of breast cancer, and is especially suitable for patients who still require HER2 inhibition after disease progression.

According to the currently globally approved indications, neratinib can be used as a single agent for early-stage adult patients with HER2-positive breast cancer who are at high risk of recurrence after completing trastuzumab-based adjuvant therapy. The establishment of this indication provides an option for breast cancer treatment to further delay recurrence, especially for those patients who still have potential risks of micrometastasis after postoperative treatment. Neratinib continues to interfere with the growth and proliferation signals of cancer cells by irreversibly inhibiting the HER2 signaling pathway, making it still clinically significant during the "post-treatment consolidation period."

In addition, neratinib is also approved for use in combination with the oral chemotherapy drug capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer, especially those who have received two or more anti-HER2 therapies (such as trastuzumab, pertuzumab, or T-DM1) in the metastatic stage but have progressed. In this combination treatment strategy, neratinib not only strengthens the interception of HER2 signals, but also shows certain penetration advantages in patients with brain metastases, striving for a longer disease control period for patients with metastatic breast cancer.

Overall, neratinib is an innovative drug with a clear positioning in the treatment of HER2-positive breast cancer. It provides sustained targeted inhibition on the basis of previous anti-HER2 treatments, bringing hope for controlling tumor progression and prolonging patient survival.

Reference materials:https://en.wikipedia.org/wiki/Neratinib